ArticleJournal of neuro-oncology2012

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.

Till Milde et al.PubMed ↗Publisher ↗

No numbers read from the abstract.